Top Markets
Coin of the day
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
株式のランク #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
株価
$0.2483
最終同期: 2026-07-31
時価総額
$2.30M
変化(1日)
-3.39%
変化(1年)
-89.01%
国
US
取引 Ensysce Biosciences, Inc. (ENSC)

カテゴリー

Ensysce Biosciences, Inc.(ENSC)のP/E比率
September 2026 時点のP/E比率 TTM -0.17
Ensysce Biosciences, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は -0.17 です。2023 年末時点での P/E は -3.39 でした。
Ensysce Biosciences, Inc. の P/E 比率の履歴(2017 〜 2026)
各年末のP/E比率
年 P/E比率 変化
2026 (TTM) -0.17 -90.20%
2024 -1.78 -47.51%
2023 -3.39 237.53%
2022 -1.00 -97.94%
2021 -48.88 -100.00%
2020 3.52M 463.02%
2019 624.36K -494.92%
2018 -158.10K -97.60%
2017 -6.60M 0.00%
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差 国
29.99 -17,298.85%
US
-18.38 10,440.25%
US
36.30 -20,911.58%
NL
-23.34 13,281.42%
AU
- -
CH
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。